TABLE 3.
Efficacy Summary
| Antitumor Activity End Point | Inavo + Palbo + Letro Arm (n = 33) | Inavo + Palbo + Fulv Arm (n = 20) |
|---|---|---|
| Patients with measurable disease | n = 25 | n = 15 |
| Best overall response, No. (%) | ||
| CR | 1 (4.0) | 0 |
| PRa | 14 (56.0) | 6 (40.0) |
| SD | 7 (28.0) | 8 (53.3) |
| PD | 3 (12.0) | 1 (6.7) |
| Best overall response rate, No. (%) | 15 (60.0) | 6 (40.0) |
| Confirmed objective response rate, No. (%) | 13 (52.0) | 6 (40.0) |
| All patients | n = 33 | n = 20 |
| Clinical benefit rate, No. (%) | 26 (78.8) | 18 (90.0) |
| PFS | ||
| Median, months (95% CI) | 23.3 (9.2 to 44.4) | 35.0 (17.7 to NE) |
Abbreviations: CR, complete response; Fulv, fulvestrant; Inavo, inavolisib; Letro, letrozole; NE, not estimable; Palbo, palbociclib; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
a
PR responses seen at all dose levels. CR response reported at the 9 mg dose level in the stage I Inavo + Palbo + Letro arm.